Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Pathol ; 212(2): 198-208, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17455169

ABSTRACT

Jam-C(-/-) mice exhibit growth retardation and multilobular pneumonia concomitant with poor survival of the mice under conventional housing conditions. The deficient mice present a mega-oesophagus and have altered airway responsiveness. In addition, the number of circulating granulocytes is increased in Jam-C(-/-) mice as compared to control animals. These phenotypes probably reflect the different functions of JAM-C expressed by endothelial and mesenchymal cells. Indeed, the deregulation in the number of circulating granulocytes is caused by the lack of JAM-C expression on endothelial cells since rescuing endothelial expression of the protein in the Jam-C(-/-) mice is sufficient to restore homeostasis. More importantly, the rescue of vascular JAM-C expression is accompanied by better survival of deficient mice, suggesting that endothelial expression of JAM-C is mandatory for animal survival from opportunistic infections and fatal pneumonia.


Subject(s)
Cell Adhesion Molecules/deficiency , Granulocytes/immunology , Homeostasis/immunology , Immunoglobulins/deficiency , Lung/immunology , Membrane Proteins/deficiency , Animals , Bronchi/immunology , Cell Adhesion Molecules/analysis , Cell Adhesion Molecules/immunology , Disease Susceptibility/immunology , Endothelial Cells/immunology , Esophageal Achalasia/immunology , Esophageal Achalasia/physiopathology , Esophagus/immunology , Esophagus/physiopathology , Immunoglobulins/analysis , Immunoglobulins/immunology , Immunohistochemistry/methods , Leukocyte Count , Lung/physiopathology , Membrane Proteins/analysis , Membrane Proteins/immunology , Mice , Mice, Mutant Strains , Muscle, Smooth/immunology , Neutrophils/immunology , Peritonitis/immunology , Peritonitis/physiopathology , Pneumonia/immunology , Receptors, CXCR4/analysis
2.
Cardiovasc Res ; 49(3): 568-81, 2001 Feb 16.
Article in English | MEDLINE | ID: mdl-11166270

ABSTRACT

The central role of vascular endothelial growth factor (VEGF) in angiogenesis in health and disease makes it attractive both as a therapeutic target for anti-angiogenic drugs and as a pro-angiogenic cytokine for the treatment of ischaemic heart disease. While VEGF binds to two receptor protein tyrosine kinases, VEGFR1 (Flt-1) and VEGFR2 (KDR), most biological functions of VEGF are mediated via VEGFR2, and the role of VEGFR1 is currently unknown. Neuropilin-1, a non-tyrosine kinase transmembrane molecule, may function as a co-receptor for VEGFR2. Considerable progress has recently been made towards delineating the signal transduction pathways distal to activation of VEGFR2. Activation of the mitogen-activated protein kinase, protein kinase C and Akt pathways are all strongly implicated in mediating diverse cellular biological functions of VEGF, including cell survival, proliferation, the generation of nitric oxide and prostacyclin and angiogenesis. Upregulation of metalloproteinases, activation of focal adhesion kinase and interactions between VEGF receptors and integrins are strongly implicated in VEGF-induced endothelial cell migration. Recent findings suggest important roles for the vasodilators nitric oxide and prostacyclin, in linking post-receptor signaling networks to downstream biological effects and in mediating some in vivo endothelial functions of VEGF.


Subject(s)
Collateral Circulation , Endothelial Growth Factors/metabolism , Endothelium, Vascular/metabolism , Immediate-Early Proteins , Lymphokines/metabolism , Milk Proteins , Myocardial Ischemia/metabolism , Neovascularization, Physiologic , Nuclear Proteins , Signal Transduction/physiology , Animals , Capillary Permeability , Cell Division , Cell Movement , DNA-Binding Proteins/genetics , Early Growth Response Protein 1 , Endothelium, Vascular/pathology , Epoprostenol/metabolism , Gene Expression Regulation , Humans , Myocardial Ischemia/pathology , Myocardial Ischemia/physiopathology , NFATC Transcription Factors , Nitric Oxide/metabolism , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-ets , Receptor Protein-Tyrosine Kinases/metabolism , Receptors, Growth Factor/metabolism , Receptors, Vascular Endothelial Growth Factor , STAT3 Transcription Factor , STAT5 Transcription Factor , Signal Transduction/genetics , Trans-Activators/genetics , Transcription Factors/genetics , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factor Receptor-1 , Vascular Endothelial Growth Factor Receptor-3 , Vascular Endothelial Growth Factors
3.
Biochem J ; 353(Pt 3): 503-12, 2001 Feb 01.
Article in English | MEDLINE | ID: mdl-11171046

ABSTRACT

We reported previously that vascular endothelial growth factor (VEGF) stimulates prostacyclin (PGI(2)) production via activation of the extracellular signal-regulated kinase (ERK) cascade. In this paper, we examined the role of protein kinase C (PKC) in this pathway. VEGF-induced PGI(2) generation and arachidonic acid release in human umbilical vein endothelial cells were inhibited by the PKC inhibitors GF109203X and calphostin C. VEGF increased PKC activity and immunoreactivity of the PKCdelta, alpha and epsilon isoforms in particulate fractions of cells. PKC inhibitors blocked VEGF-induced activation of ERK, MEK (mitogen-activated protein kinase kinase) and the cytosolic phospholipase A(2), but had little effect on ERK activation induced by basic fibroblast growth factor. GF109203X, calphostin C and the PKCdelta-selective inhibitor, rottlerin, did not inhibit activation of the KDR receptor for VEGF. Inhibition of Ca(2+) fluxes using BAPTA/AM [1,2-bis-(o-aminophenoxy)ethane-N,N,N',N'-tetra-acetic acid tetrakis(acetoxymethyl ester)] blocked VEGF-induced PGI(2) production but did not inhibit ERK activation. Neither activation nor inhibition of the NO/cGMP pathway had any effect on VEGF induction of ERK activity and PGI(2) synthesis. Wortmannin partially inhibited VEGF stimulation of PGI(2) production, but did not inhibit VEGF-induced ERK activity. VEGF-induced ERK activation and PGI(2) production were blocked by rottlerin, and VEGF increased association of PKCdelta with Raf-1, the upstream activator of MEK. The PKC-selective inhibitor Go6976 did not inhibit ERK activation and had only a partial effect on PGI(2) production. These findings indicate that activation of PKC plays a crucial role in VEGF signalling via the ERK cascade leading to PGI(2) synthesis and suggest that the PKCdelta isoform may be a key mediator of VEGF-induced activation of the ERK pathway via increased association with Raf-1.


Subject(s)
Calcium/metabolism , Endothelial Growth Factors/physiology , Epoprostenol/biosynthesis , Isoenzymes/metabolism , Lymphokines/physiology , Mitogen-Activated Protein Kinases/metabolism , Protein Kinase C/metabolism , Cells, Cultured , Enzyme Activation , Humans , Protein Kinase C-delta , Radioligand Assay , Signal Transduction , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...